Drug-eluting stents

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 169-178

  Woods, T Cooper ^a   Marks, Andrew R ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

Paclitaxel; Rapamycin; Restenosis; Sirolimus; Taxol

Indexed keywords

PACLITAXEL; RADIOACTIVE MATERIAL; RAPAMYCIN;

CELL PROLIFERATION; CLINICAL EXAMINATION; CLINICAL TRIAL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MARKETING; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; SOLID; UNITED STATES; VASCULAR SMOOTH MUSCLE;

DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GRAFT OCCLUSION, VASCULAR; HUMANS; STENTS;

EID: 1542299129     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.105243     Document Type: Review

References (51)

1. Williams DO, Holubkov R, Yeh W, et al. 2000. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 102:2945-51
2. Berger E, Williams DO, Reinert S, et al. 1986. Sustained efficacy of percutaneous transluminal coronary angioplasty. Am. Heart J. 111:233-36
3. Block PC. 1980. Percutaneous transluminal coronary angioplasty. Am. J. Roentgenol. 135:955-59
4. Holmes DR Jr. 2003. State of the art in coronary intervention. Am. J. Cardiol 91:50A-53A
5. Marx SO, Marks AR. 2001. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104:852-55
6. Jayaraman T, Marks AR. 1993. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J. Biol. Chem. 268:25385-88
7. Marx SO, Jayaraman T, Go LO, et al. 1995. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 76:412-17
8. Poon M, Marx SO, Gallo R, et al. 1996. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 98:2277-83
9. Topol EJ, Lincoff AM, Kereiakes DJ, et al. 2002. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. 113:1-6
10. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. 1995. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol. 76:1222-27
11. Welt FG, Rogers C. 2002. Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol. 22:1769-76
12. Ross R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115-26
13. Ross R. 1999. Atherosclerosis is an inflammatory disease. Am. Heart J. 138:8419-20
14. Mudra H, Regar E, Klauss V, et al. 1997. Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neointimal proliferation without significant reference segment response. Circulation 95:363-70
15. Heuser R, Houser F, Culler SD, et al. 2000. A retrospective study of 6,671 patients comparing coronary stenting and balloon angioplasty. J. Invasive. Cardiol. 12:354-62
16. Serruys PW, de Jaegere P, Kiemeneij F, et al. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331:489-95
17. Fischman DL, Leon MB, Baim DS, et al. 1994. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331:496-501
18. Kimmel SE, Localio AR, Brensinger C, et al. 2000. Effects of coronary stents on cardiovascular outcomes in broad-based clinical practice. Arch. Intern. Med. 160:2593-99
19. Rogers CDK. 2002. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. Rev. Cardiovasc. Med. 3:810-15
20. Suselbeck T, Latsch A, Siri H, et al. 2001. Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus. Am. J. Cardiol. 88:243-47
21. Gallo R, Padurean A, Chesebro JH, et al. 1998. Inhibition of intimai thickening after balloon angioplasty in porcine coronary arteries by rapamycin. Circulation 99:2164-70
22. Sabers CJ, Martin MM, Brunn GJ, et al. 1995. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270:815-22
23. Bresnahan WA, Boldogh I, Ma T, et al. 1996. Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle. Cell Growth Differ. 7:1283-90
24. Koff A, Polyak K. 1995. P27KIP1, an inhibitor of cyclin-dependent kinases. Prog. Cell Cycle Res. 1:141-47
25. Luo Y, Marx SO, Kiyokawa H, et al. 1996. Rapamycin resistance tied to defective regulation of p27Kipl. Mol. Cell. Biol. 16:6744-51
26. Brunn GJ, Hudson CC, Sekulic A, et al. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101
27. Burnett PE, Barrow RK, Cohen NA, et al. 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95:1432-37
28. Marx SO, Marks AR. 1999. Cell cycle progression and proliferation despite 4BP-1 dephosphorylation. Mol. Cell Biol. 19: 6041-47
29. Schiff PB, Fant J, Horwitz SB. 1979. Promotion of microtubule assembly in vitro by taxol. Nature 277:665-67
30. Schiff PB, Horwitz SB. 1980. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 77:1561-65
31. Dugina VB, Alexandrova AY, Lane K, et al. 1995. The role of the microtubular system in the cell response to HGF/SF. J. Cell Sci. 108(Pt. 4):1659-67
32. Rosette C, Karin M. 1995. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B. J. Cell Biol. 128:1111-19
33. Pletjushkina OJ, Ivanova OJ, Kaverina IN, et al. 1994. Taxol-treated fibroblasts acquire an epithelioid shape and a circular pattern of actin bundles. Exp. Cell Res. 212:201-8
34. Rosania GR, Swanson JA. 1996. Microtubules can modulate pseudopod activity from a distance inside macrophages. Cell Motil. Cytoskelet. 34:230-45
35. Rowinsky EK, Donehower RC, Jones RJ, et al. 1988. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48:4093-100
36. De Brabander M, Geuens G, Nuydens R, et al. 1981. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc. Natl. Acad. Sci. USA 78:5608-612
37. Hafeez N. 2002. Prevention of coronary restenosis with radiation therapy: a review. Clin. Cardiol. 25:313-22
38. Carter AJ, Fischell TA. 1998. Current status of radioactive stents for the prevention of in-stent restenosis. Int. J. Radiat. Oncol. Biol. Phys. 41:127-33
39. 32P radioactive beta-emitting stent implantation in patients with coronary artery disease: the Milan Dose-Response Study. Circulation 101:18-26
40. Sousa JE, Costa MA, Abizaid A, et al. 2001. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103:192-95
41. Sousa JE, Costa MA, Sousa AG, et al. 2003. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107:381-83
42. Morice MC, Serruys PW, Sousa JE, et al. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:1773-80
43. Moses JW, Leon MB, Popma JJ, et al. 2002. SIRIUS: a U.S. multicenter, randomized, double-blind study of the SIRolImUS-eluting stent in de novo native coronary lesions. Presented at Transcatheter Cardiovascular Therapeutics Conf., Washington, DC, Sep. 24-28
44. Grube E, Silber S, Hauptmann KE, et al. 2003. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42
45. Columbo A. 2002. TAXUS-II international study cohort 1: slow-release formulation -six month results intent to treat analysis. Presented at Transcatheter Cardiovascular Therapeutics Conf., Washington, DC, Sep. 24-28
46. Columbo A. 2002. TAXUS-II international study cohort II: moderate-release formulation - six month results intent to treat analysis. Presented at Transcatheter Cardiovascular Therapeutics Conf., Washington, DC, Sep. 24-28
47. Tanabe K, Serruys PW, Grube E, et al. 2003. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107:559-64
48. 2003. Guidant Reports Preliminary Results of DELIVER Clinical Trial. Guidant Corp., Indianapolis, IN
49. de la Fuente LM, Miano J, Mrad J, et al. 2001. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) registry (BARDDS) in human subjects. Catheter Cardiovasc. Interv. 53:480-88
50. 2002. Guidant Halts Further Development on Actinomycin-D Drug Eluting Stent Program. Guidant Corp., Indianapolis, IN
51. 2003. Guidant Reports Positive Six-Month Clinical Results of Everolimus Eluting Coronary Stent. Guidant Corp., Indianapolis, IN